Elacestrant: Clinical Pearls for Adverse Effect Management

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses what has been learned about the safety profile of elacestrant and shares clinical pearls for adverse event management, aimed at helping patients remain on therapy while maximizing their quality of life.

EP: 1.Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC

EP: 2.Episode 2: Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1 mutations with other alterations

EP: 4.Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease

EP: 5.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

Now Viewing

EP: 6.Elacestrant: Clinical Pearls for Adverse Effect Management

EP: 7.Emerging data on oral selective estrogen receptor degraders

Recent Videos